Health economic evaluation of non-pharmaceutical interventions for COVID-19 prevention and control: a systematic review_Chinese Journal of Evidence-Based Medicine

Authors：

WENG Junling ^1,2 , LIAN Dai ^1,2 , TAO Ying ^1,2 , LUO Bingxing ^1,2 , LI Fuming ^1,2 , YAN Juntao ^1,2 ,  YANG Yi ^1,2 ,  CHEN Yingyao ^1,2

1. School of Public Health, Fudan University, Shanghai 200032, P. R. China;
2. National Health Commission Key Laboratory of Health Technology Assessment, Fudan University, Shanghai 200032, P. R. China;

Corresponding author：

YANG Yi, Email: fd_yangyi@fudan.edu.cn; CHEN Yingyao, Email: yychen@shmu.edu.cn

Keywords：

COVID-19; Non-pharmaceutical interventions; Health economic evaluation; Systematic review

DOI：

10.7507/1672-2531.202302021

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review the economy of non-pharmaceutical interventions (NPIs) for COVID-19. Methods The Web of Science, PubMed, EMbase, Cochrane Library, INAHTA, CNKI, WanFang Data and SinoMed databases were electronically searched to collect studies on health economic evaluations from 1 January 2020 to 20 August 2022. Then the included materials were reviewed, extracted and data integration analysis were conducted based on inclusion and exclusion criteria. Results Seventy-one academic publications were finally included, which contained 25 papers about nucleic acid testing, antigen testing and screening, 5 papers about personal protection, 12 papers about social distancing, quarantine and isolation, 11 papers about regional or national lockdown and 18 papers about multiple NPIs. The results showed that compared with no intervention, nucleic acid testing, antigen testing, screening and personal protection measures were economical. Social distancing, quarantine and isolation were also economical compared with no intervention. However, in low-income countries, movement restriction and factory shutdown may exact a heavy toll on the poorest and most vulnerable. Moreover, compared with a single long-term lockdown, multiple short-term lockdowns could be more economical, but the cost was still huge overall. Conclusion NPIs such as nucleic acid testing, antigen testing, personal protection, social distancing, quarantine, isolation and factory shutdown are economical. Although regional or national lockdown can save lives, it is not suitable for wide use. The researches on specific populations, specific variants (especially Omicron) and in the context of China need to be carried out.

Citation： WENG Junling, LIAN Dai, TAO Ying, LUO Bingxing, LI Fuming, YAN Juntao, YANG Yi, CHEN Yingyao. Health economic evaluation of non-pharmaceutical interventions for COVID-19 prevention and control: a systematic review. Chinese Journal of Evidence-Based Medicine, 2023, 23(6): 654-664. doi: 10.7507/1672-2531.202302021 Copy

1.	Ashraf BN. Economic impact of government interventions during the COVID-19 pandemic: international evidence from financial markets. J Behav Exp Finance, 2020, 27: 100371.
2.	Kim DD, Neumann PJ. Analyzing the cost effectiveness of policy responses for COVID-19: the importance of capturing social consequences. Med Decis Making, 2020, 40(3): 251-253.
3.	Hamadeh N, Rompa CV, Metreau E, et al. New World Bank country classifications by income level: 2022-2023.
4.	Paltiel AD, Zheng A, Walensky RP. Assessment of SARS-CoV-2 screening strategies to permit the safe reopening of college campuses in the United States. JAMA Netw Open, 16818.
5.	Savitsky LM, Albright CM. Preventing COVID-19 transmission on labor and delivery: a decision analysis. Am J Perinatol, 2020, 37(10): 1031-1037.
6.	Currie J, Adamson J, Bowden B, et al. Impact of a novel community testing pathway for people with suspected COVID-19 in Wales: a cost-minimisation analysis. BMJ Open, 2020, 10(8): e038017.
7.	Jiang Y, Cai D, Chen D, et al. The cost-effectiveness of conducting three versus two reverse transcription-polymerase chain reaction tests for diagnosing and discharging people with COVID-19: evidence from the epidemic in Wuhan, China. BMJ Glob Health, 2020, 5(7): e002690.
8.	Kilkon K, Hong M. Estimation of the impact of comprehensive COVID-19 testing in South Korea: a cost-benefit analysis using the extended SEIR model. Korean J of Polic Stud, 2020, 35(3): 141-168.
9.	Lim JT, Dickens BL, Cook AR, et al. The costs of an expanded screening criteria for COVID-19: a modelling study. Int J Infect Dis, 2020, 100: 490-496.
10.	Paltiel AD, Zheng A, Sax PE. Clinical and economic effects of widespread rapid testing to decrease SARS-CoV-2 transmission. Ann Intern Med, 2021, 174(6): 803-810.
11.	Neilan AM, Losina E, Bangs AC, et al. Clinical impact, costs, and cost-effectiveness of expanded severe acute respiratory syndrome coronavirus 2 testing in Massachusetts. Clin Infect Dis, 2021, 73(9): 2908-2917.
12.	Love J, Wimmer MT, Toth DJA, et al. Comparison of antigen- and RT-PCR-based testing strategies for detection of SARS-CoV-2 in two high-exposure settings. PLoS One, 2021, 16(9): e0253407.
13.	Stevenson M, Metry A, Messenger M. Modelling of hypothetical SARS-CoV-2 point-of-care tests on admission to hospital from A&E: rapid cost-effectiveness analysis. Health Technol Assess, 2021, 25(21): 1-68.
14.	Stevenson M, Metry A, Messenger M. Modelling of hypothetical SARS-CoV-2 point of care tests for routine testing in residential care homes: rapid cost-effectiveness analysis. Health Technol Assess, 2021, 25(39): 1-74.
15.	何栩如, 孙喜琢, 宫芳芳, 等. 大规模人群新冠病毒核酸筛查成本效益分析. 现代医院, 2021, 21(9): 1403-1406.
16.	黄勇, 倪莉红, 陈远源, 等. 广州市新型冠状病毒肺炎病例主动筛查的成本效果评价. 现代预防医学, 2021, 48(1): 97-100.
17.	Segui FL, Cuxart OE, Villar OMI, et al. A cost-benefit analysis of the COVID-19 asymptomatic mass testing strategy in the North Metropolitan area of Barcelona. Int J Environ Res Public Health, 2021, 18(13): 7028.
18.	Segui FL, Duran JMN, Tuldra A, et al. Impact of mass workplace COVID-19 rapid testing on health and healthcare resource savings. Int J Environ Res Public Health, 2021, 18(13): 7129.
19.	Cherian P, Krishna S, Menon GI. Optimizing testing for COVID-19 in India. PLoS Comput Biol, 2021, 17(7): e1009126.
20.	Galderisi A, Lolli E, Cavicchiolo ME, et al. The aftermath of SARS-CoV-2 in NICU: saving or checking accounts. projected cost-effectiveness analysis. Eur J Pediatr, 2021, 180(5): 1631-1635.
21.	Maya S, Padda G, Close V, et al. Optimal strategies to screen health care workers for COVID-19 in the US: a cost-effectiveness analysis. Cost Eff Resour Alloc, 2022, 20(1): 2.
22.	Maya S, McCorvie R, Jacobson K, et al. COVID-19 testing strategies for K-12 schools in California: a cost-effectiveness analysis. Int J Environ Res Public Health, 2022, 19(15): 9371.
23.	Diel R, Nienhaus A. Point-of-care COVID-19 antigen testing in German emergency rooms - a cost-benefit analysis. Pulmonology, 2022, 28(3): 164-172.
24.	Gandjour A. Benefits, risks, and cost-effectiveness of COVID-19 self-tests from a consumer’s perspective. BMC Health Serv Res, 2022, 22(1): 47.
25.	Domínguez C, García R, Sánchez J, et al. Evaluation of cost-benefit and measures during the COVID-19 pandemic for incoming travelers through tests in origin in Spain. Front Public Health, 2022, 10: 816406.
26.	Karnon J, Afzali HHA, Bonevski B. An economic evaluation of government-funded COVID-19 testing in Australia. Appl Health Econ Health Policy, 2022, 20(5): 681-691.
27.	de Assis TSM, Freire ML, Carvalho JP, et al. Cost-effectiveness of anti-SARS-CoV-2 antibody diagnostic tests in Brazil. PLoS One, 2022, 17(2): e0264159.
28.	Wang X, Cai Y, Zhang B, et al. Cost-effectiveness analysis on COVID-19 surveillance strategy of large-scale sports competition. Infect Dis Poverty, 2022, 11(1): 32.
29.	Olaniyi S, Obabiyi OS, Okosun KO, et al. Mathematical modelling and optimal cost-effective control of COVID-19 transmission dynamics. Eur Phys J Plus, 2020, 135(11): 938.
30.	Risko N, Werner K, Offorjebe OA, et al. Cost-effectiveness and return on investment of protecting health workers in low- and middle-income countries during the COVID-19 pandemic. PLoS One, 2020, 15(10): e0240503.
31.	Bagepally BS, Haridoss M, Natarajan M, et al. Cost-effectiveness of surgical mask, N-95 respirator, hand-hygiene and surgical mask with hand hygiene in the prevention of COVID-19: cost effectiveness analysis from Indian context. Clin Epidemiol Glob Health, 2021, 10: 100702.
32.	Kazungu J, Munge K, Werner K, et al. Examining the cost-effectiveness of personal protective equipment for formal healthcare workers in Kenya during the COVID-19 pandemic. BMC Health Serv Res, 2021, 21(1): 992.
33.	Kapinos KA, Salley JR, Day A. Brief cost analysis of surgical personal protective equipment during the COVID-19 pandemic. Value Health, 2022, 25(8): 1317-1320.
34.	Khajji B, Kada D, Balatif O, et al. A multi-region discrete time mathematical modeling of the dynamics of COVID-19 virus propagation using optimal control. J Appl Math Comput, 2020, 64(1-2): 255-281.
35.	Suwantika AA, Zakiyah N, Diantini A, et al. The role of administrative and secondary data in estimating the costs and effects of school and workplace closures due to the COVID-19 pandemic. DATA, 2020, 5(4): 98.
36.	Thunstrom L, Newbold SC, Finnoff D, et al. The benefits and costs of using social distancing to flatten the curve for COVID-19. J Benefit-Cost Anal, 2020, 11(2): 179-195.
37.	Zala D, Mosweu I, Critchlow S, et al. Costing the COVID-19 pandemic: an exploratory economic evaluation of hypothetical suppression policy in the United Kingdom. Value Health, 2020, 23(11): 1432-1437.
38.	Broughel J, Kotrous M. The benefits of coronavirus suppression: a cost-benefit analysis of the response to the first wave of COVID-19 in the United States. PLoS One, 2021, 16(6): e0252729.
39.	Zhao J, Jin H, Li X, et al. Disease burden attributable to the first wave of COVID-19 in China and the effect of timing on the cost-effectiveness of movement restriction policies. Value Health, 2021, 24(5): 615-624.
40.	Grafton RQ, Parslow J, Kompas T, et al. Epidemiological modelling of the health and economic effects of COVID-19 control in Australia's second wave. Z Gesundh Wiss, 2021, 1-16.
41.	Kouidere A, Youssoufi LE, Ferjouchia H, et al. Optimal control of mathematical modeling of the spread of the COVID-19 pandemic with highlighting the negative impact of quarantine on diabetics people with cost-effectiveness. Chaos Solitons Fractals, 2021, 145: 110777.
42.	Barnett-Howell Z, Watson OJ, Mobarak AM. The benefits and costs of social distancing in high- and low-income countries. Trans R Soc Trop Med Hyg, 2021, 115(7): 807-819.
43.	Barlow MT, Marshall ND, Tyson RC. Optimal shutdown strategies for COVID-19 with economic and mortality costs: British Columbia as a case study. R Soc Open Sci, 2021, 8(9): 202255.
44.	Suwantika AA, Dhamanti I, Suharto Y, et al. The cost-effectiveness of social distancing measures for mitigating the COVID-19 pandemic in a highly-populated country: a case study in Indonesia. Travel Med Infect Dis, 2022, 45: 102245.
45.	Gandjour A. The clinical and economic value of a successful shutdown during the SARS-CoV-2 pandemic in Germany. Q Rev Econ Finance, 2022, 84: 502-509.
46.	Rowthorn R, Maciejowski J. A cost-benefit analysis of the COVID-19 disease. Oxf Rev Econ Policy, 2020, 36: S38-S55.
47.	Miles D, Stedman M, Heald A. Living with COVID-19: balancing costs against benefits in the face of the virus. Natl Inst Econ Rev, 2020, 253: R60-R76.
48.	Miles DK, Stedman M, Heald AH. "Stay at home, protect the national health service, save lives": a cost benefit analysis of the lockdown in the United Kingdom. Int J Clin Pract, 2021, 75(3): e13674.
49.	Shlomai A, Leshno A, Sklan EH, et al. Modeling social distancing strategies to prevent SARS-CoV-2 spread in Israel: a cost-effectiveness analysis. Value Health, 2021, 24(5): 607-614.
50.	Blakely T, Thompson J, Bablani L, et al. Association of simulated COVID-19 policy responses for social restrictions and lockdowns with health-adjusted life-years and costs in Victoria, Australia. JAMA Health Forum, 2021, 2(7): e211749.
51.	Robles-Zurita J. Reducing the basic reproduction number of COVID-19: a model simulation focused on QALYs, hospitalisation, productivity costs and optimal (soft) lockdown. Eur J Health Econ, 2022, 1-13.
52.	Tildesley MJ, Vassall A, Riley S, et al. Optimal health and economic impact of non-pharmaceutical intervention measures prior and post vaccination in England: a mathematical modelling study. R Soc Open Sci, 2022, 9(8): 211746.
53.	Yakusheva O, van den Broek-Altenburg E, Brekke G, et al. Lives saved and lost in the first six month of the US COVID-19 pandemic: a retrospective cost-benefit analysis. PLoS One, 2022, 17(1): e0261759.
54.	Gandjour A. Cost-effectiveness of future lockdown policies against the COVID-19 pandemic. Health Serv Manage Res, 2023, 36(1): 51-62.
55.	Lally M. A cost-benefit analysis of COVID-19 lockdowns in Australia. Monash Bioeth Rev, 2022, 40(1): 62-93.
56.	Ferguson EA, Brum E, Chowdhury A, et al. Modelling how face masks and symptoms-based quarantine synergistically and cost-effectively reduce SARS-CoV-2 transmission in Bangladesh. Epidemics, 2022, 40: 100592.
57.	Asamoah JKK, Owusu MA, Jin Z, et al. Global stability and cost-effectiveness analysis of COVID-19 considering the impact of the environment: using data from Ghana. Chaos Solitons Fractals, 2020, 140: 110103.
58.	Eilersen A, Sneppen K. Cost-benefit of limited isolation and testing in COVID-19 mitigation. Sci Rep, 2020, 10(1): 18543.
59.	Baggett TP, Scott JA, Le MH, et al. Clinical outcomes, costs, and cost-effectiveness of strategies for adults experiencing sheltered homelessness during the COVID-19 pandemic. JAMA Netw Open, 2020, 3(12): e2028195.
60.	Losina E, Leifer V, Millham L, et al. College campuses and COVID-19 mitigation: clinical and economic value. Ann Intern Med, 2021, 174(4): 472-483.
61.	Zafari Z, Goldman L, Kovrizhkin K, et al. The cost-effectiveness of common strategies for the prevention of transmission of SARS-CoV-2 in universities. PLoS One, 2021, 16(9): e0257806.
62.	Du Z, Pandey A, Bai Y, et al. Comparative cost-effectiveness of SARS-CoV-2 testing strategies in the USA: a modelling study. Lancet Public Health, 2021, 6(3): e184-e191.
63.	Ebigbo A, Römmele C, Bartenschlager C, et al. Cost-effectiveness analysis of SARS-CoV-2 infection prevention strategies including pre-endoscopic virus testing and use of high risk personal protective equipment. Endoscopy, 2021, 53(2): 156-161.
64.	Reddy KP, Shebl FM, Foote JHA, et al. Cost-effectiveness of public health strategies for COVID-19 epidemic control in South Africa: a microsimulation modelling study. Lancet Glob Health, 2021, 9(2): e120-e129.
65.	Thom H, Walker J, Vickerman P, et al. Exploratory comparison of healthcare costs and benefits of the UK's COVID-19 response with four European countries. Eur J Public Health, 2021, 31(3): 619-624.
66.	吕秋莹, 温莹, 孔东锋, 等. 深圳市新型冠状病毒肺炎精准防控措施的卫生经济学评价. 预防医学论坛, 2021, 27(10): 748-751.
67.	Asamoah JKK, Jin Z, Sun GQ, et al. Sensitivity assessment and optimal economic evaluation of a new COVID-19 compartmental epidemic model with control interventions. Chaos Solitons Fractals, 2021, 146: 110885.
68.	Lopez-Valcarcel BG, Vallejo-Torres L. The costs of COVID-19 and the cost-effectiveness of testing. Appl Econ Appl, 2021, 29(85): 77-89.
69.	Wang Q, Shi NY, Huang JX, et al. Cost-effectiveness of public health measures to control COVID-19 in China: a microsimulation modeling study. Front Public Health, 2022, 9: 726690.
70.	Yuan Y, Li N. Optimal control and cost-effectiveness analysis for a COVID-19 model with individual protection awareness. Physica A, 2022, 603: 127804.
71.	李浩楠, 张慧. 及时开展新冠疫情防控与大规模核酸检测的卫生经济学评价. 现代预防医学, 2022, 49(7): 1252-1258.
72.	Bilinski A, Ciaranello A, Fitzpatrick MC, et al. Estimated transmission outcomes and costs of SARS-CoV-2 diagnostic testing, screening, and surveillance strategies among a simulated population of primary school students. JAMA Pediatr, 2022, 176(7): 679-689.
73.	Asamoah JKK, Okyere E, Abidemi A, et al. Optimal control and comprehensive cost-effectiveness analysis for COVID-19. Results Phys, 2022, 33: 105177.
74.	Guzmán Ruiz Y, Vecino-Ortiz AI, Guzman-Tordecilla N, et al. Cost-effectiveness of the COVID-19 test, trace and isolate program in Colombia. Lancet Reg Health Am, 2022, 6: 100109.
75.	Palladino R, Bollon J, Ragazzoni L, et al. Effect of implementation of the lockdown on the number of COVID-19 deaths in four European countries. Disaster Med Public Health Prep, 2021, 15(4): 40-42.
76.	Hogan AB, Jewell BL, Sherrard-Smith E, et al. Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: a modelling study. Lancet Glob Health, 2020, 8(9): 1132-1141.
77.	Siu JY. Health inequality experienced by the socially disadvantaged populations during the outbreak of COVID-19 in Hong Kong: an interaction with social inequality. Health Soc Care Community, 2021, 29(5): 1522-1529.
78.	Liu Y, Mao B, Liang S, et al. Association between age and clinical characteristics and outcomes of COVID-19. Eur Respir J, 2020, 55(5): 2001112.
79.	Zhang XN, Tan Y, Ling Y, et al. Viral and host factors related to the clinical outcome of COVID-19. Nature, 2020, 583(7816): 437-440.
80.	Zimmermann P, Curtis N. Why does the severity of COVID-19 differ with age. :understanding the mechanisms underlying the age gradient in outcome following SARS-CoV-2 infection. Pediatr Infect Dis J, 2022, 41(2): 36-45.
81.	Goldman JD, Robinson PC, Uldrick TS, et al. COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies. J Immunother Cancer, 2021, 9(6): e002630.
82.	吴俣, 刘珏, 刘民, 等. 新型冠状病毒Omicron变异株亚型BA. 4与BA. 5的流行病学特征及防控研究. 中国全科医学, 2022, 25(30): 3721-3725.
83.	Liu Y, Rocklöv J. The effective reproductive number of the Omicron variant of SARS-CoV-2 is several times relative to Delta. J Travel Med, 2022, 29(3): taac037.
84.	Liu Y, Rocklöv J. The reproductive number of the Delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus. J Travel Med, 2021, 28(7): taab124.
85.	张佳琦, 刘国华, 黄建安. 新型冠状病毒奥密克戎变异株的研究进展. 实用临床医药杂志, 2022, 26(19): 143-148.

1. Ashraf BN. Economic impact of government interventions during the COVID-19 pandemic: international evidence from financial markets. J Behav Exp Finance, 2020, 27: 100371.
2. Kim DD, Neumann PJ. Analyzing the cost effectiveness of policy responses for COVID-19: the importance of capturing social consequences. Med Decis Making, 2020, 40(3): 251-253.
3. Hamadeh N, Rompa CV, Metreau E, et al. New World Bank country classifications by income level: 2022-2023.
4. Paltiel AD, Zheng A, Walensky RP. Assessment of SARS-CoV-2 screening strategies to permit the safe reopening of college campuses in the United States. JAMA Netw Open, 16818.
5. Savitsky LM, Albright CM. Preventing COVID-19 transmission on labor and delivery: a decision analysis. Am J Perinatol, 2020, 37(10): 1031-1037.
6. Currie J, Adamson J, Bowden B, et al. Impact of a novel community testing pathway for people with suspected COVID-19 in Wales: a cost-minimisation analysis. BMJ Open, 2020, 10(8): e038017.
7. Jiang Y, Cai D, Chen D, et al. The cost-effectiveness of conducting three versus two reverse transcription-polymerase chain reaction tests for diagnosing and discharging people with COVID-19: evidence from the epidemic in Wuhan, China. BMJ Glob Health, 2020, 5(7): e002690.
8. Kilkon K, Hong M. Estimation of the impact of comprehensive COVID-19 testing in South Korea: a cost-benefit analysis using the extended SEIR model. Korean J of Polic Stud, 2020, 35(3): 141-168.
9. Lim JT, Dickens BL, Cook AR, et al. The costs of an expanded screening criteria for COVID-19: a modelling study. Int J Infect Dis, 2020, 100: 490-496.
10. Paltiel AD, Zheng A, Sax PE. Clinical and economic effects of widespread rapid testing to decrease SARS-CoV-2 transmission. Ann Intern Med, 2021, 174(6): 803-810.
11. Neilan AM, Losina E, Bangs AC, et al. Clinical impact, costs, and cost-effectiveness of expanded severe acute respiratory syndrome coronavirus 2 testing in Massachusetts. Clin Infect Dis, 2021, 73(9): 2908-2917.
12. Love J, Wimmer MT, Toth DJA, et al. Comparison of antigen- and RT-PCR-based testing strategies for detection of SARS-CoV-2 in two high-exposure settings. PLoS One, 2021, 16(9): e0253407.
13. Stevenson M, Metry A, Messenger M. Modelling of hypothetical SARS-CoV-2 point-of-care tests on admission to hospital from A&E: rapid cost-effectiveness analysis. Health Technol Assess, 2021, 25(21): 1-68.
14. Stevenson M, Metry A, Messenger M. Modelling of hypothetical SARS-CoV-2 point of care tests for routine testing in residential care homes: rapid cost-effectiveness analysis. Health Technol Assess, 2021, 25(39): 1-74.
15. 何栩如, 孙喜琢, 宫芳芳, 等. 大规模人群新冠病毒核酸筛查成本效益分析. 现代医院, 2021, 21(9): 1403-1406.
16. 黄勇, 倪莉红, 陈远源, 等. 广州市新型冠状病毒肺炎病例主动筛查的成本效果评价. 现代预防医学, 2021, 48(1): 97-100.
17. Segui FL, Cuxart OE, Villar OMI, et al. A cost-benefit analysis of the COVID-19 asymptomatic mass testing strategy in the North Metropolitan area of Barcelona. Int J Environ Res Public Health, 2021, 18(13): 7028.
18. Segui FL, Duran JMN, Tuldra A, et al. Impact of mass workplace COVID-19 rapid testing on health and healthcare resource savings. Int J Environ Res Public Health, 2021, 18(13): 7129.
19. Cherian P, Krishna S, Menon GI. Optimizing testing for COVID-19 in India. PLoS Comput Biol, 2021, 17(7): e1009126.
20. Galderisi A, Lolli E, Cavicchiolo ME, et al. The aftermath of SARS-CoV-2 in NICU: saving or checking accounts. projected cost-effectiveness analysis. Eur J Pediatr, 2021, 180(5): 1631-1635.
21. Maya S, Padda G, Close V, et al. Optimal strategies to screen health care workers for COVID-19 in the US: a cost-effectiveness analysis. Cost Eff Resour Alloc, 2022, 20(1): 2.
22. Maya S, McCorvie R, Jacobson K, et al. COVID-19 testing strategies for K-12 schools in California: a cost-effectiveness analysis. Int J Environ Res Public Health, 2022, 19(15): 9371.
23. Diel R, Nienhaus A. Point-of-care COVID-19 antigen testing in German emergency rooms - a cost-benefit analysis. Pulmonology, 2022, 28(3): 164-172.
24. Gandjour A. Benefits, risks, and cost-effectiveness of COVID-19 self-tests from a consumer’s perspective. BMC Health Serv Res, 2022, 22(1): 47.
25. Domínguez C, García R, Sánchez J, et al. Evaluation of cost-benefit and measures during the COVID-19 pandemic for incoming travelers through tests in origin in Spain. Front Public Health, 2022, 10: 816406.
26. Karnon J, Afzali HHA, Bonevski B. An economic evaluation of government-funded COVID-19 testing in Australia. Appl Health Econ Health Policy, 2022, 20(5): 681-691.
27. de Assis TSM, Freire ML, Carvalho JP, et al. Cost-effectiveness of anti-SARS-CoV-2 antibody diagnostic tests in Brazil. PLoS One, 2022, 17(2): e0264159.
28. Wang X, Cai Y, Zhang B, et al. Cost-effectiveness analysis on COVID-19 surveillance strategy of large-scale sports competition. Infect Dis Poverty, 2022, 11(1): 32.
29. Olaniyi S, Obabiyi OS, Okosun KO, et al. Mathematical modelling and optimal cost-effective control of COVID-19 transmission dynamics. Eur Phys J Plus, 2020, 135(11): 938.
30. Risko N, Werner K, Offorjebe OA, et al. Cost-effectiveness and return on investment of protecting health workers in low- and middle-income countries during the COVID-19 pandemic. PLoS One, 2020, 15(10): e0240503.
31. Bagepally BS, Haridoss M, Natarajan M, et al. Cost-effectiveness of surgical mask, N-95 respirator, hand-hygiene and surgical mask with hand hygiene in the prevention of COVID-19: cost effectiveness analysis from Indian context. Clin Epidemiol Glob Health, 2021, 10: 100702.
32. Kazungu J, Munge K, Werner K, et al. Examining the cost-effectiveness of personal protective equipment for formal healthcare workers in Kenya during the COVID-19 pandemic. BMC Health Serv Res, 2021, 21(1): 992.
33. Kapinos KA, Salley JR, Day A. Brief cost analysis of surgical personal protective equipment during the COVID-19 pandemic. Value Health, 2022, 25(8): 1317-1320.
34. Khajji B, Kada D, Balatif O, et al. A multi-region discrete time mathematical modeling of the dynamics of COVID-19 virus propagation using optimal control. J Appl Math Comput, 2020, 64(1-2): 255-281.
35. Suwantika AA, Zakiyah N, Diantini A, et al. The role of administrative and secondary data in estimating the costs and effects of school and workplace closures due to the COVID-19 pandemic. DATA, 2020, 5(4): 98.
36. Thunstrom L, Newbold SC, Finnoff D, et al. The benefits and costs of using social distancing to flatten the curve for COVID-19. J Benefit-Cost Anal, 2020, 11(2): 179-195.
37. Zala D, Mosweu I, Critchlow S, et al. Costing the COVID-19 pandemic: an exploratory economic evaluation of hypothetical suppression policy in the United Kingdom. Value Health, 2020, 23(11): 1432-1437.
38. Broughel J, Kotrous M. The benefits of coronavirus suppression: a cost-benefit analysis of the response to the first wave of COVID-19 in the United States. PLoS One, 2021, 16(6): e0252729.
39. Zhao J, Jin H, Li X, et al. Disease burden attributable to the first wave of COVID-19 in China and the effect of timing on the cost-effectiveness of movement restriction policies. Value Health, 2021, 24(5): 615-624.
40. Grafton RQ, Parslow J, Kompas T, et al. Epidemiological modelling of the health and economic effects of COVID-19 control in Australia's second wave. Z Gesundh Wiss, 2021, 1-16.
41. Kouidere A, Youssoufi LE, Ferjouchia H, et al. Optimal control of mathematical modeling of the spread of the COVID-19 pandemic with highlighting the negative impact of quarantine on diabetics people with cost-effectiveness. Chaos Solitons Fractals, 2021, 145: 110777.
42. Barnett-Howell Z, Watson OJ, Mobarak AM. The benefits and costs of social distancing in high- and low-income countries. Trans R Soc Trop Med Hyg, 2021, 115(7): 807-819.
43. Barlow MT, Marshall ND, Tyson RC. Optimal shutdown strategies for COVID-19 with economic and mortality costs: British Columbia as a case study. R Soc Open Sci, 2021, 8(9): 202255.
44. Suwantika AA, Dhamanti I, Suharto Y, et al. The cost-effectiveness of social distancing measures for mitigating the COVID-19 pandemic in a highly-populated country: a case study in Indonesia. Travel Med Infect Dis, 2022, 45: 102245.
45. Gandjour A. The clinical and economic value of a successful shutdown during the SARS-CoV-2 pandemic in Germany. Q Rev Econ Finance, 2022, 84: 502-509.
46. Rowthorn R, Maciejowski J. A cost-benefit analysis of the COVID-19 disease. Oxf Rev Econ Policy, 2020, 36: S38-S55.
47. Miles D, Stedman M, Heald A. Living with COVID-19: balancing costs against benefits in the face of the virus. Natl Inst Econ Rev, 2020, 253: R60-R76.
48. Miles DK, Stedman M, Heald AH. "Stay at home, protect the national health service, save lives": a cost benefit analysis of the lockdown in the United Kingdom. Int J Clin Pract, 2021, 75(3): e13674.
49. Shlomai A, Leshno A, Sklan EH, et al. Modeling social distancing strategies to prevent SARS-CoV-2 spread in Israel: a cost-effectiveness analysis. Value Health, 2021, 24(5): 607-614.
50. Blakely T, Thompson J, Bablani L, et al. Association of simulated COVID-19 policy responses for social restrictions and lockdowns with health-adjusted life-years and costs in Victoria, Australia. JAMA Health Forum, 2021, 2(7): e211749.
51. Robles-Zurita J. Reducing the basic reproduction number of COVID-19: a model simulation focused on QALYs, hospitalisation, productivity costs and optimal (soft) lockdown. Eur J Health Econ, 2022, 1-13.
52. Tildesley MJ, Vassall A, Riley S, et al. Optimal health and economic impact of non-pharmaceutical intervention measures prior and post vaccination in England: a mathematical modelling study. R Soc Open Sci, 2022, 9(8): 211746.
53. Yakusheva O, van den Broek-Altenburg E, Brekke G, et al. Lives saved and lost in the first six month of the US COVID-19 pandemic: a retrospective cost-benefit analysis. PLoS One, 2022, 17(1): e0261759.
54. Gandjour A. Cost-effectiveness of future lockdown policies against the COVID-19 pandemic. Health Serv Manage Res, 2023, 36(1): 51-62.
55. Lally M. A cost-benefit analysis of COVID-19 lockdowns in Australia. Monash Bioeth Rev, 2022, 40(1): 62-93.
56. Ferguson EA, Brum E, Chowdhury A, et al. Modelling how face masks and symptoms-based quarantine synergistically and cost-effectively reduce SARS-CoV-2 transmission in Bangladesh. Epidemics, 2022, 40: 100592.
57. Asamoah JKK, Owusu MA, Jin Z, et al. Global stability and cost-effectiveness analysis of COVID-19 considering the impact of the environment: using data from Ghana. Chaos Solitons Fractals, 2020, 140: 110103.
58. Eilersen A, Sneppen K. Cost-benefit of limited isolation and testing in COVID-19 mitigation. Sci Rep, 2020, 10(1): 18543.
59. Baggett TP, Scott JA, Le MH, et al. Clinical outcomes, costs, and cost-effectiveness of strategies for adults experiencing sheltered homelessness during the COVID-19 pandemic. JAMA Netw Open, 2020, 3(12): e2028195.
60. Losina E, Leifer V, Millham L, et al. College campuses and COVID-19 mitigation: clinical and economic value. Ann Intern Med, 2021, 174(4): 472-483.
61. Zafari Z, Goldman L, Kovrizhkin K, et al. The cost-effectiveness of common strategies for the prevention of transmission of SARS-CoV-2 in universities. PLoS One, 2021, 16(9): e0257806.
62. Du Z, Pandey A, Bai Y, et al. Comparative cost-effectiveness of SARS-CoV-2 testing strategies in the USA: a modelling study. Lancet Public Health, 2021, 6(3): e184-e191.
63. Ebigbo A, Römmele C, Bartenschlager C, et al. Cost-effectiveness analysis of SARS-CoV-2 infection prevention strategies including pre-endoscopic virus testing and use of high risk personal protective equipment. Endoscopy, 2021, 53(2): 156-161.
64. Reddy KP, Shebl FM, Foote JHA, et al. Cost-effectiveness of public health strategies for COVID-19 epidemic control in South Africa: a microsimulation modelling study. Lancet Glob Health, 2021, 9(2): e120-e129.
65. Thom H, Walker J, Vickerman P, et al. Exploratory comparison of healthcare costs and benefits of the UK's COVID-19 response with four European countries. Eur J Public Health, 2021, 31(3): 619-624.
66. 吕秋莹, 温莹, 孔东锋, 等. 深圳市新型冠状病毒肺炎精准防控措施的卫生经济学评价. 预防医学论坛, 2021, 27(10): 748-751.
67. Asamoah JKK, Jin Z, Sun GQ, et al. Sensitivity assessment and optimal economic evaluation of a new COVID-19 compartmental epidemic model with control interventions. Chaos Solitons Fractals, 2021, 146: 110885.
68. Lopez-Valcarcel BG, Vallejo-Torres L. The costs of COVID-19 and the cost-effectiveness of testing. Appl Econ Appl, 2021, 29(85): 77-89.
69. Wang Q, Shi NY, Huang JX, et al. Cost-effectiveness of public health measures to control COVID-19 in China: a microsimulation modeling study. Front Public Health, 2022, 9: 726690.
70. Yuan Y, Li N. Optimal control and cost-effectiveness analysis for a COVID-19 model with individual protection awareness. Physica A, 2022, 603: 127804.
71. 李浩楠, 张慧. 及时开展新冠疫情防控与大规模核酸检测的卫生经济学评价. 现代预防医学, 2022, 49(7): 1252-1258.
72. Bilinski A, Ciaranello A, Fitzpatrick MC, et al. Estimated transmission outcomes and costs of SARS-CoV-2 diagnostic testing, screening, and surveillance strategies among a simulated population of primary school students. JAMA Pediatr, 2022, 176(7): 679-689.
73. Asamoah JKK, Okyere E, Abidemi A, et al. Optimal control and comprehensive cost-effectiveness analysis for COVID-19. Results Phys, 2022, 33: 105177.
74. Guzmán Ruiz Y, Vecino-Ortiz AI, Guzman-Tordecilla N, et al. Cost-effectiveness of the COVID-19 test, trace and isolate program in Colombia. Lancet Reg Health Am, 2022, 6: 100109.
75. Palladino R, Bollon J, Ragazzoni L, et al. Effect of implementation of the lockdown on the number of COVID-19 deaths in four European countries. Disaster Med Public Health Prep, 2021, 15(4): 40-42.
76. Hogan AB, Jewell BL, Sherrard-Smith E, et al. Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: a modelling study. Lancet Glob Health, 2020, 8(9): 1132-1141.
77. Siu JY. Health inequality experienced by the socially disadvantaged populations during the outbreak of COVID-19 in Hong Kong: an interaction with social inequality. Health Soc Care Community, 2021, 29(5): 1522-1529.
78. Liu Y, Mao B, Liang S, et al. Association between age and clinical characteristics and outcomes of COVID-19. Eur Respir J, 2020, 55(5): 2001112.
79. Zhang XN, Tan Y, Ling Y, et al. Viral and host factors related to the clinical outcome of COVID-19. Nature, 2020, 583(7816): 437-440.
80. Zimmermann P, Curtis N. Why does the severity of COVID-19 differ with age. :understanding the mechanisms underlying the age gradient in outcome following SARS-CoV-2 infection. Pediatr Infect Dis J, 2022, 41(2): 36-45.
81. Goldman JD, Robinson PC, Uldrick TS, et al. COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies. J Immunother Cancer, 2021, 9(6): e002630.
82. 吴俣, 刘珏, 刘民, 等. 新型冠状病毒Omicron变异株亚型BA. 4与BA. 5的流行病学特征及防控研究. 中国全科医学, 2022, 25(30): 3721-3725.
83. Liu Y, Rocklöv J. The effective reproductive number of the Omicron variant of SARS-CoV-2 is several times relative to Delta. J Travel Med, 2022, 29(3): taac037.
84. Liu Y, Rocklöv J. The reproductive number of the Delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus. J Travel Med, 2021, 28(7): taab124.
85. 张佳琦, 刘国华, 黄建安. 新型冠状病毒奥密克戎变异株的研究进展. 实用临床医药杂志, 2022, 26(19): 143-148.

Chinese Journal of Evidence-Based Medicine

Health economic evaluation of non-pharmaceutical interventions for COVID-19 prevention and control: a systematic review

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content